Sentence examples for difference in enhancement of from inspiring English sources

There was no significant difference in enhancement of the liver, spleen, pancreas, or renal cortex when we compared intra-arterial and intravenous administration.

To understand the large difference in enhancement of device performance, a dimensionless quality factor Q LSPR defined as the ratio of the enhanced localized field around the NP and the incident field was derived and calculated for the NS and NR [56].

While there was no significant difference in enhancement of IGABA through GABAA receptors with either β2 or β3 subunits, incorporation of β1 subunits reduced enhancement of IGABA (see also Fig. 2B).

As only in the IV group a small statistical significant difference in enhancement of the brainstem was measured in this study, the ability of the IA protocol to supply contrast rich blood to the brainstem, cerebellum and caudal cerebrum should be considered a potential limitation of the protocol.

The measurement results showed that the threshold field of single carbon nanofibers with different lengths was in the range of 4 5 V/μm with a corresponding emission current density of 20 μA/cm2, but an evident difference in the enhancement of emitted current between nanofibers of different lengths could be found when the applied field was increased continuously.

It is still unclear as to the origin of the difference in enhancement observed between our ATP sensor and the tobramycin sensor.

The difference in the enhancement of the Nusselt number for different particle materials is due to the difference in their particle heat transport in nanofluids.

It is difficult to provide an explanation for the difference in enhancement found in our study especially because we designed this study to show equal enhancement of the two concentrations.

Although MRI contrast enhancement and washout characteristics have been used for the characterization of adrenal masses, recent studies have demonstrated no significant difference in enhancement characteristics between benign and malignant adrenal lesions[ 24 26].

The basis for this difference in the enhancement of myelotoxicity is not clear, as all the drugs are potent PARP-1 inhibitors.

They were able to show a dependence of enhancement kinetics on VEGF expression, and demonstrated differences in enhancement parameters between different histological tumour types and between malignant and benign disease.